Placebo (SAD)

DRUG5 trials

Sponsors

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd., Idorsia Pharmaceuticals Ltd., Pharmacobio, RNATICS GmbH

Conditions

Alzheimer DiseaseHealthyHealthy Chinese VolunteersHealthy VolunteersPharmacokineticsSafetyTolerability

Phase 1

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349

CompletedNCT03610867

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Healthy Chinese Volunteers

Start: 2017-04-27End: 2017-08-31Updated: 2018-08-02

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

CompletedNCT04183686

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2019-11-25End: 2020-03-15Updated: 2020-08-12

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

CompletedNCT04798209

Idorsia Pharmaceuticals Ltd.Healthy

Start: 2021-01-29End: 2022-05-21Updated: 2022-06-21

A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People

RecruitingNCT06367426

PharmacobioAlzheimer Disease

Start: 2024-04-30End: 2025-05-31Target: 100Updated: 2024-04-16

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

RecruitingNCT06752122

RNATICS GmbHHealthy Volunteers, Pharmacokinetics, Safety +1

Start: 2025-02-18End: 2026-08-31Target: 24Updated: 2025-11-20